Q-omics provides the consensus-scored KSR1 profile across patient tissues and cancer cell-line models. KSR1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KSR1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KSR1 RNA expression shows 20,886 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where KSR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KSR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KSR1 survival associations across molecular data types. KSR1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KSR1 RNA expression–survival associations across cancer types. High KSR1 expression shows unfavorable associations in LIHC, ACC and KIRP, but favorable associations in KIRC, UCS and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KSR1 RNA expression.
This table summarizes KSR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KSR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KSR1 shows lower tumor expression in THCA, KICH, BRCA and UCEC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher KSR1 RNA expression in tumor versus normal tissue (log2 FC = +2.196, t-test p < 0.001).
This table shows molecular features associated with KSR1 in patient tissues and cancer cell lines. In patient samples, KSR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KSR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
